InMode Ltd.

Equities

INMD

IL0011595993

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 02:25:24 2024-05-28 pm EDT			5-day change	1st Jan Change
19.4 ^USD	+4.98%		+3.87%	-12.43%

May. 03	UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating	MT
May. 02	InMode Shares Rise; Q1 Non-GAAP Earnings, Revenue Fall; 2024 Guidance Cut	MT

InMode Ltd. Provides Revenue Guidance for the Fourth Quarter 2021 and Full Year 2022

January 12, 2022 at 07:30 am EST

InMode Ltd. provided revenue guidance for the fourth quarter 2021 and full year 2022. Record revenue for the fourth quarter in the range of $109.5 million to $110 million.

Full year 2022 revenue in the range of $415 million to $425 million.

Latest news about InMode Ltd.

UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating	May. 03	MT
InMode Shares Rise; Q1 Non-GAAP Earnings, Revenue Fall; 2024 Guidance Cut	May. 02	MT
Transcript : InMode Ltd., Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (INMD) INMODE Posts Q1 EPS $0.32, vs. Street Est of $0.41	May. 02	MT
InMode Ltd. announces an Equity Buyback for 8,370,000 shares.	May. 02	CI
InMode Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
InMode Ltd. Revises Earnings Guidance for the Full Year Ending December 31, 2024	May. 02	CI
InMode Ltd. authorizes a Buyback Plan.	Apr. 30	CI
Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating	Apr. 12	MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	Apr. 09	MT
InMode Lowers Fiscal 2024 Revenue Forecast, Issues Fiscal Q1 Guidance	Apr. 09	MT
Inmode Ltd. Provides Revenue Guidance for the First Quarter of 2024	Apr. 09	CI
Glass Lewis Issues Shareholders Alert on InMode Ahead of Annual Meeting	Mar. 20	MT
InMode Seeks M&A	Mar. 13	CI
Transcript : InMode Ltd. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM	Mar. 13
Barclays Adjusts Price Target on InMode to $34 From $32, Maintains Overweight Rating	Feb. 15	MT
UBS Adjusts InMode Price Target to $26 From $24, Maintains Neutral Rating	Feb. 14	MT
InMode's Q4 Non-GAAP Earnings, Revenue Fall; 2024 Guidance Issued	Feb. 13	MT
Transcript : InMode Ltd., Q4 2023 Earnings Call, Feb 13, 2024	Feb. 13
Earnings Flash (INMD) INMODE Posts Q4 EPS $0.71, vs. Street Est of $0.67	Feb. 13	MT
InMode Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
InMode Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
North American Morning Briefing : Stocks Seen -2-	Feb. 13	DJ
Barclays Trims Price Target on InMode to $32 From $33, Maintains Overweight Rating	Jan. 18	MT
InMode Ltd. Provides Revenue Guidance for the Fourth Quarter, Full Year of 2023 and for the Full Year of 2024	Jan. 16	CI

Chart InMode Ltd.

Duration

Period

More charts

Company Profile

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and womenâs health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-05 - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for InMode Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18.48 USD

Average target price

25.6 USD

Spread / Average Target

+38.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
INMODE LTD.	-12.43%	1.56B
THERMO FISHER SCIENTIFIC	+7.74%	223B
DANAHER CORPORATION	+11.56%	195B
INTUITIVE SURGICAL, INC.	+18.84%	144B
BOSTON SCIENTIFIC CORPORATION	+30.01%	111B
SIEMENS HEALTHINEERS AG	+2.32%	65.19B
EDWARDS LIFESCIENCES CORPORATION	+13.85%	53.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	50.28B
AGILENT TECHNOLOGIES, INC.	+6.76%	44.15B
GE HEALTHCARE TECHNOLOGIES INC.	+1.80%	36.45B

Other Advanced Medical Equipment & Technology